KemPharm Analyst Ratings
KemPharm Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2022 | 81.16% | HC Wainwright & Co. | $11 → $10 | Maintains | Buy |
| 01/31/2022 | 99.28% | HC Wainwright & Co. | $10 → $11 | Upgrades | Neutral → Buy |
| 04/09/2021 | 81.16% | HC Wainwright & Co. | $12 → $10 | Maintains | Neutral |
| 03/04/2021 | 117.39% | HC Wainwright & Co. | $24 → $12 | Downgrades | Buy → Neutral |
| 01/25/2021 | 407.25% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 05/20/2020 | -72.83% | HC Wainwright & Co. | $2.5 → $1.5 | Reiterates | → Buy |
| 11/20/2019 | -54.71% | HC Wainwright & Co. | $3 → $2.5 | Reiterates | → Buy |
| 09/05/2019 | -80.98% | Roth Capital | $4.25 → $1.05 | Downgrades | Buy → Neutral |
| 06/19/2019 | -45.65% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
| 05/23/2018 | 207.97% | Janney Montgomery Scott | → $17 | Initiates Coverage On | → Buy |
| 02/26/2018 | 99.28% | Canaccord Genuity | $7 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/17/2022 | 81.16% | HC Wainwright & Co. | 11 美元 → 10 美元 | 維護 | 購買 |
| 01/31/2022 | 99.28% | HC Wainwright & Co. | 10 美元 → 11 美元 | 升級 | 中性 → 買入 |
| 2021 年 9 月 4 日 | 81.16% | HC Wainwright & Co. | 12 美元 → 10 美元 | 維護 | 中立 |
| 2021 年 4 月 3 日 | 117.39% | HC Wainwright & Co. | 24 美元 → 12 美元 | 降級 | 買入 → 中性 |
| 01/25/2021 | 407.25% | 羅斯資本 | → 28 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/20/2020 | -72.83% | HC Wainwright & Co. | 2.5 美元 → 1.5 美元 | 重申 | → 購買 |
| 2019 年 11 月 20 日 | -54.71% | HC Wainwright & Co. | $3 → 2.5 美元 | 重申 | → 購買 |
| 09/05/2019 | -80.98% | 羅斯資本 | 4.25 美元 → 1.05 美元 | 降級 | 買入 → 中性 |
| 06/19/2019 | -45.65% | HC Wainwright & Co. | → 3 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/23/2018 | 207.97% | 詹尼蒙哥馬利斯科特 | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2018 年 2 月 26 日 | 99.28% | Canaccord Genu | 7 美元 → 11 美元 | 維護 | 購買 |
KemPharm Questions & Answers
KempHarm 問題與解答
The latest price target for KemPharm (NASDAQ: KMPH) was reported by HC Wainwright & Co. on August 17, 2022. The analyst firm set a price target for $10.00 expecting KMPH to rise to within 12 months (a possible 81.16% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年8月17日公佈了KemPharm（納斯達克股票代碼：KMPH）的最新目標股價。該分析公司將目標股價設定爲10.00美元，預計KMPH將在12個月內上漲至10.00美元（可能上漲81.16％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for KemPharm (NASDAQ: KMPH) was provided by HC Wainwright & Co., and KemPharm maintained their buy rating.
KemPharm（納斯達克股票代碼：KMPH）的最新分析師評級由HC Wainwright & Co. 提供，KemPharm維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KemPharm, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KemPharm was filed on August 17, 2022 so you should expect the next rating to be made available sometime around August 17, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與KemPharm的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。KemPharm的最後一次評級是在2022年8月17日提交的，因此您應該預計下一個評級將在2023年8月17日左右公佈。
While ratings are subjective and will change, the latest KemPharm (KMPH) rating was a maintained with a price target of $11.00 to $10.00. The current price KemPharm (KMPH) is trading at is $5.52, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的KemPharm（KMPH）評級維持不變，目標股價爲11.00美元至10.00美元。KemPharm（KMPH）目前的交易價格爲5.52美元，超出了分析師的預測區間。